Abstract
AbstractWe develop and estimate a dynamic structural model of demand in a setting where product characteristics endogenously evolve in response to aggregate consumer choices. The direction and speed of innovation are inefficient because individuals do not account for their influence on innovation, creating an externality. Our application focuses on drugs invented to combat human immunodeficiency virus; they differ in their efficacy and propensity to cause side effects. We find that the externality is quantitatively important; temporarily subsidizing the experimental treatment would have increased average social welfare by improving average health and would have reduced inequality in lifetime utility across health groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
